Olimpia Radu, MD
Geriatric Medicine · Riverside, RINPI 1447247788
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,548 and has fallen 91.3% since, to $135 in 2025. Among geriatric medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$421
- Boehringer Ingelheim$226
- Actelion Pharmaceuticals US, Inc.$172
- Grifols USA, LLC$149
- Novartis$146
- Sunovion Pharmaceuticals Inc.$129
- plus $667 from 16 others
What the payments were for
- Food & beverage$1,909100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 36 | $421 |
| Boehringer Ingelheim | 5 | $226 |
| Actelion Pharmaceuticals US, Inc. | 10 | $172 |
| Grifols USA, LLC | 7 | $149 |
| Novartis | 9 | $146 |
| Sunovion Pharmaceuticals Inc. | 9 | $129 |
| AstraZeneca(2 entities) | 7 | $115 |
| Mallinckrodt Enterprises LLC | 8 | $111 |
| Regeneron Healthcare Solutions, Inc. | 5 | $88 |
| Jazz Pharmaceuticals Inc. | 3 | $65 |
| Johnson & Johnson | 4 | $53 |
| Insmed, Inc. | 2 | $35 |
| Merck | 2 | $29 |
| Circassia Inc. | 2 | $24 |
| Philips North America LLC | 2 | $23 |
| Vapotherm Inc | 1 | $22 |
| Electromed, Inc. | 2 | $19 |
| Sanofi | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$1,909 in reported general payments places this provider in the 90th percentile of 28 geriatric medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $44,471 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,339 |
| Dalfampridine ErDalfampridine | 13 | $9,087 |
| XareltoRivaroxaban | 28 | $7,895 |
| MyrbetriqMirabegron | 28 | $6,091 |
| EntrestoSacubitril/Valsartan | 15 | $5,078 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,863 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,846 |
| Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol | 13 | $2,880 |
| Levothyroxine Sodium | 126 | $2,100 |
| Duloxetine Hcl | 31 | $1,981 |
| Baclofen | 14 | $1,978 |
| Lisinopril | 115 | $1,956 |
| Atorvastatin Calcium | 114 | $1,892 |
| Arformoterol Tartrate | 22 | $1,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $44,47196 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $421 | $26,04943 claims |
| Johnson & JohnsonXarelto | $53 | $7,89528 claims |
| NovartisEntresto | $146 | $5,07815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 geriatric medicine providers in Rhode Island.
Other geriatric medicine in Riverside
- Richard BesdineRiverside$740
- Julio Defillo DraibyRiverside$151
- Nadia MujahidRiverside$99
- Aman NandaRiverside$57
- Carla WilliamsRiverside$54
- Sakeena RazaRiverside$22
- Rohit TyagiRiverside$0
- Iva NeupaneRiverside$0
- Michael KlufasCumberland$37K
- John StoukidesEast Providence$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.